A randomised, placebo-controlled, double blind, crossover trial on the effect of a 20:1 cannabidiol: Δ9-tetrahydrocannabinol medical cannabis product on neurocognition, attention, and mood.
European Neuropsychopharmacology May 2024 Brooke Manning, Amie C Hayley, Sarah J Catchlove et al.
As cannabinoid-based medications gain popularity in the treatment of refractory medical conditions, it is crucial to examine the neurocognitive effects of commonly prescribed products to ensure associated safety profiles. The present study aims to investigate the acute effects of a standard 1 mL sublingual dose of CannEpil®, a medicinal cannabis oil containing 100 mg cannabidiol (CBD) and 5 mg...
DOI: 10.1016/j.euroneuro.2024.02.002 (opens in new tab)
Full text (opens in new tab)
Cannabidiol
Attention
Cantab
Visuospatial memory
+1